Objective: This study aims to examine whether blood pressure reductions differ by estrogen use among overweight glucose-intolerant women.
N umerous clinical trials have demonstrated that lifestyle interventions targeting weight reduction in overweight individuals also reduce blood pressure levels. 1<4 In the Diabetes Prevention Program (DPP), intensive lifestyle change (ILS) led to reductions in systolic blood pressure (SBP) and diastolic blood pressure (DBP), 5 with persistent benefits observed up to 10 years later. 1 Whether blood pressure reductions differ between estrogen users and nonusers is not known. Randomized trials of exogenous estrogen therapy have reported that oral estrogen use increases blood pressure, 6<8 decreases blood pressure, 9, 10 or has no effect on blood pressure 11<13 in postmenopausal women. These conflicting results could be attributed to the paradoxical effects of oral estrogen, which may increase the activation of the renin-angiotensin system 10 while simultaneously causing peripheral vasodilatation and endothelial remodeling. 14 Therefore, use of oral estrogen could potentiate or negate the effects of weight loss interventions on blood pressure. Among postmenopausal women, a potential mechanism for the effects of weight loss on blood pressure is concurrent alteration in endogenous sex hormone profiles, specifically decreases in endogenous estradiol (E 2 ), testosterone, and dehydroepiandrosterone (DHEA), and increases in the binding protein sex hormoneYbinding globulin (SHBG) . No randomized trials have reported whether endogenous sex hormone levels are associated with blood pressure changes independently of changes in body mass in postmenopausal women. Observational studies are inconsistent, with some studies reporting associations between higher E 2 and testosterone levels and between lower SHBG levels and higher SBP and DBP, 15, 16 whereas other reports note no association. 17, 18 Using DPP data, we have previously reported that postmenopausal participants randomized to ILS had significant reductions in weight and waist circumference compared with placebo. 19 Therefore, in a secondary analysis of the DPP, we hypothesized that decreases in blood pressure among women randomized to ILS would be observed among both users and nonusers of exogenous estrogen and that the magnitude of such reductions in our overweight dysglycemic sample would be similar by estrogen use. We also hypothesized that reductions in blood pressure would be associated with reductions in sex steroids and increases in SHBG.
METHODS
The characteristics of DPP participants 20<22 and the characteristics of participants in this secondary analysis have been published. 19 Briefly, the DPP was a randomized controlled trial conducted between 1996 and 2001. The DPP was originally developed to prevent or delay the onset of diabetes among persons at high risk using interventions designed to improve abnormal glucose metabolism. The DPP had 26 clinical centers located throughout the United States, which are listed in the Appendix (Supplemental Digital Content 1, http://links.lww.com/MENO/A61). Eligible participants were randomly assigned to one of three groups: metformin 850 mg twice daily, placebo twice daily, or ILS. The goals of ILS were to achieve and to maintain a weight reduction of at least 7% of initial body weight through consumption of a lowcalorie, low-fat diet plus moderate physical activity for at least 150 minutes/week. 22 Inclusion criteria included the following: 25 years or older, fasting plasma glucose level of 95 to 125 mg/dL, 2-hour plasma glucose level of 140 to 200 mg/dL after a 75-g glucose load, and body mass index (BMI) of 24 kg/m 2 or higher (Q22 kg/m 2 for Asian Americans). A written informed consent form was obtained from all participants before screening, consistent with the guidelines of each participating center's institutional review board.
At the time of randomization, all women completed a questionnaire about their menses, gynecological history (including surgical operations), and estrogen use (contraceptive and postmenopausal therapy). Medication use was reassessed every 6 months. For this report, we included women who were postmenopausal at randomization, who had an available stored blood sample, and who consented to participate in ancillary studies. We did not include women enrolled at the Native American/American Indian centers, as these women did not originally consent to participate in this ancillary study. Women were classified as postmenopausal if they met any of the following criteria: bilateral oophorectomy, lack of menses for at least 1 year but with intact uterus and at least one ovary, cessation of menses before hysterectomy, cessation of menses within the past year and older than 55 years, and cessation of menses with hysterectomy and 55 years or older. Women could be categorized as oral estrogen users both at randomization and at 1-year follow-up (n = 324), or as nonusers both at randomization and at 1-year follow-up (n = 382). Women who used injectable, implantable, transdermal, or transvaginal estrogen were excluded, as were women who used any estrogen at baseline but not on follow-up and vice versa. We have previously reported the characteristics of estrogen use 19 : of the 324 women who reported using oral estrogen at baseline and on follow-up, 266 women were estrogen-only users at baseline and 58 women used estrogen-progestogen; at 1-year follow-up, 258 women were estrogen-only users and 66 women used estrogen-progestogen, and the estrogen most commonly used were conjugated equine estrogens.
Weight and waist circumference were measured semiannually, and participants had an annual blood pressure measurement. Blood pressure measurements were performed by certified staff, using a standard mercury manometer, at baseline and quarterly visits following a standard protocol, with the participant seated for at least 5 minutes before the measurement. A second pressure measurement was obtained 30 seconds later after complete cuff deflation. The mean of the two measurements was used for analysis. Hypertension was defined as blood pressure higher than 140/90 mm Hg or the use of antihypertensive medication. Changes in blood pressure medication doses were not recorded. Blood was drawn after a 12-hour fast at baseline and annually thereafter.
We have previously reported sex hormone measurement procedures. 23 Briefly, SHBG, follicle-stimulating hormone (FSH), total E 2 , total testosterone, and DHEA were measured on heparinized plasma collected at baseline and 1 year. SHBG was measured at Endoceutics (Quebec city, Canada) using enzyme-linked immunosorbent assay (Bioline), with interassay coefficients of variation of 7.8 and 5.0 at 18.2 and 63.1 nmol/L, respectively. FSH was measured at Endoceutics using enzyme-linked immunosorbent assay (Bioline), with interassay coefficients of variation of 3.6 and 4.4 at 27.1 and 72.9 mIU/mL, respectively. E 2 , testosterone, and DHEA were analyzed at Endoceutics using gas chromatography/mass spectrometry. The limits of detection were 3.0 pg/mL for total E 2 , 8.0 ng/dL for total testosterone, and 0.30 ng/mL for DHEA. The interassay coefficients of variation were 17.5% at 4.7 pg/mL for E 2 , 13.0% at 14 ng/dL for testosterone, and 24.0% at 0.77 ng/mL for DHEA.
Statistical analysis
Women who did not use any estrogen at baseline or on follow-up were compared with women who used oral estrogen both at baseline and on follow-up. For each sample or estrogen group, baseline characteristics were described using percentages for categorical variables and mean (SD) for quantitative variables. Baseline sex hormone distributions were skewed; therefore, log-transformed values and median values were used for the comparison of these baseline distributions. We used t tests or Wilcoxon rank sum tests to compare changes in SBP and DBP between randomized treatment arms. In the DPP, maximal reductions in weight loss were noted 1 year after randomization; therefore, we examined blood pressure changes between baseline and 1 year. 22 Change in blood pressure was calculated as 1-year level j baseline level. Next, the magnitudes of blood pressure changes among women randomized to ILS, metformin, and placebo were compared between estrogen users and nonusers. We examined the association between sex hormone changes and blood pressure changes separately for estrogen users and nonusers. Owing to differences in baseline FSH by randomization arm and previously reported effects of menopausal stage on sex steroidY adipose tissue relationship, 24 baseline FSH levels were also examined as a covariate. A series of linear regression models additionally adjusted for age, race/ethnicity, and use of blood pressure medications.
In sensitivity analyses, we also evaluated models that adjusted for changes in waist circumference and fasting insulin. Waist circumference and weight are highly correlated; we decided to use waist circumference because of its stronger association with reductions in adiposity among postmenopausal women enrolled in weight loss interventions. 25 Characteristics of estrogen-only and estrogen-progestogen users did not differ (results not shown); therefore, these women were grouped together. Finally, in models that contained estrogen users and nonusers, we evaluated the significance of an interaction term between estrogen use and intervention arm for outcomes of changes in weight, waist circumference, and sex hormones. We also evaluated the significance of an interaction term between hormone use and sex hormone level among women randomized to ILS for outcomes of changes in SBP and DBP. The SAS analysis system was used for all analyses (SAS Institute, Cary, NC).
RESULTS
Baseline characteristics of postmenopausal women by estrogen use are shown in Table 1 . The baseline prevalences of hypertension (defined by blood pressure levels or use of blood pressure medications) were similar by estrogen use. There were no significant differences in DBP by estrogen use, whereas SBP was slightly but significantly lower among women using oral estrogen. Use of blood pressure medications at baseline was also similar between estrogen users and nonusers. All women were overweight or obese and glucose-intolerant at baseline, reflecting DPP recruitment criteria. Women who did not use estrogen were slightly older and more often nonwhite than estrogen users. Among nonusers, the most common cause of menopause was natural or nonsurgical cessation of menses, whereas among estrogen users, the most common cause of menopause was oophorectomy. Nonusers weighed more, had greater waist circumference, and had higher BMI than estrogen users. Nonusers had higher baseline levels of fasting insulin and FSH but lower baseline levels of SHBG and E 2 than estrogen users. Differences in testosterone level between estrogen users and nonusers were not observed; DHEA was slightly higher in nonusers. Among women who did not use estrogen, there were no significant baseline differences between women randomized to ILS (n = 133), women randomized to metformin (n = 122), and women randomized to placebo (n = 129), except that women randomized to metformin had slightly lower FSH levels than women randomized to placebo (51.5 vs 59.3 IU/L, P = 0.02). Among estrogen users, there were no significant baseline differences between women randomized to ILS (n = 107), women randomized to metformin (n = 122), and women randomized to placebo (n = 95), except that there were slightly more African-American women in the metformin arm than in the placebo arm (9% vs 5%, P = 0.02). Table 2 shows reductions in weight and waist circumference by intervention arm among women who used and did not use estrogen. Among both estrogen users and nonusers, women randomized to ILS or metformin lost weight and reduced waist circumference compared with placebo. The magnitude of weight loss and waist circumference reduction did not differ significantly by estrogen use, within or across randomization arms. Table 2 also shows changes in SHBG and sex steroid levels by estrogen use. Among women who did not use estrogen, randomization to ILS was associated with increases in SHBG and decreases in DHEA compared with placebo; randomization to ILS was not associated with significant sex hormone changes among women randomized to metformin compared with placebo. However, the interaction term between randomization arm and estrogen use was not significant. The exception was that the interaction between hormone use and intervention arm for changes in E 2 levels was significant, suggesting that estrogen use modified metformin effects on E 2 levels; however, in stratified analysis, metformin did not decrease E 2 levels relative to placebo among estrogen users or nonusers. Figure 1 illustrates corresponding changes in blood pressure by randomization arm and by estrogen use. Among estrogen users, women randomized to ILS had reductions in SBP (P = 0.016) and DBP (P = 0.009) compared with placebo. Women randomized to metformin had nonsignificant changes in SBP (P = 0.59) and DBP (P = 0.19) compared with placebo. Among women who did not use estrogen, women randomized to ILS had significant reductions in DBP (P = 0.001) compared with placebo, although reductions in SBP did not meet criteria for significance (P = 0.11) compared with placebo. Women randomized to metformin had nonsignificant reductions in SBP (P = 0.53) and DBP (P = 0.53).
When we compared the magnitudes of blood pressure reduction by estrogen use, particularly in the ILS arm, where significant decreases in blood pressure were observed, we found no significant differences by estrogen use (Fig. 1) . That is, both estrogen users and nonusers randomized to ILS had a similar magnitude of reductions in SBP (P = 0.45) and DBP (P = 0.16). Use of blood pressure medication at 1-year follow-up was also similar by estrogen use (21% among nonusers and 27% among users, P = 0.10).
We did not find statistically significant associations between changes in blood pressure and changes in sex hormones. Specifically, among women randomized to ILS, where the largest blood pressure reductions were observed, sex hormone changes were not associated with changes in SBP or DBP in unadjusted models or in models that adjusted for age, race/ethnicity, blood pressure medication use, and FSH; in models that also adjusted for waist circumference and 1/fasting insulin; in models stratified by estrogen use that included the entire sample of women and adjusted for randomization arm; and in models that included all women and evaluated the interaction between sex hormone level and estrogen use.
DISCUSSION
In a secondary analysis of a randomized trial of weight loss interventions in overweight postmenopausal women, we found that elective estrogen users and nonusers had similar patterns of blood pressure reductions. Among both estrogen users and nonusers, women randomized to ILS had greater decreases in blood pressure, whereas women randomized to metformin had nonsignificant decreases in blood pressure despite significant decreases in weight and waist circumference compared with placebo. The magnitude of blood pressure reductions among women in the ILS arm and the proportion of women using blood pressure medications at 1-year follow-up were also similar by estrogen use. To our knowledge, no other randomized studies have examined whether the use of oral estrogen reduces the effects of lifestyle on blood pressure, particularly for postmenopausal women who are at risk for adverse cardiovascular events (ie, overweight and glucose-intolerant).
Our results are reassuring in that estrogen use does not completely negate the beneficial effects of lifestyle change on weight and blood pressure. In observational studies, estrogen use has been reported to be associated with increased blood pressure levels. 26, 27 Reports of randomized trials conflict, with reports of increased blood pressure versus placebo, 6<8 no effect on blood pressure, 11<13 or lowered blood pressure. 9, 10 Previous studies have reported that randomized trials of lifestyle modification in postmenopausal women can improve metabolic syndrome components, specifically blood pressure. 28, 29 These reductions are highly correlated with reductions in fat mass. 28 Weight loss was associated with concurrent reductions in adipokines, such as C-reactive protein and tumor necrosis factor->, that might have contributed to decreases in blood pressure. 28 Our results suggest that the magnitude of weight loss necessary for blood pressure reduction needs to be fairly large among overweight glucose-intolerant women, as the women randomized to ILS lost more weight than those randomized to metformin, and only women randomized to ILS had concomitant reductions in blood pressure. Although women randomized to ILS lost approximately 7 kg of weight regardless of estrogen use, accompanying reductions in SBP and DBP were only 3 to 5 mm Hg. This suggests that smaller amounts of weight loss (ie, aimed at targets less than the DPP ILS target of 7% of total body weight) might not lead to significant blood pressure declines.
Although we observed changes in sex hormone profiles, particularly increases in SHBG levels among women randomized to ILS, these changes were not significantly associated with declines in SBP or DBP among estrogen users and nonusers. Although no randomized trials have examined the role of sex hormones in altering blood pressure levels, observational studies have suggested that endogenous sex steroid levels might also contribute to blood pressure levels, despite conflicting reports. In the Multi-Ethnic Study of Atherosclerosis, higher baseline DHEA, E 2 , and testosterone and lower baseline SHBG predicted incident hypertension and increases in blood pressure levels, 15 with associations between blood pressure and SHBG and DHEA persisting after adjustment for BMI. Similar results were observed in a Swedish cohort of middle-aged women. 16 Among women in the Beaver Dam Eye Study, SHBG was strongly and inversely associated with DBP, whereas greater testosterone was associated with greater SBP and DBP; relationships between estrone and blood pressure and between DHEA and blood pressure were not observed. 30 In contrast, a cross-sectional report from the Study of Women's Health Across the Nation did not find significant associations between SHBG and SBP or DBP after adjustment for BMI. 17 A similar lack of association was reported among women enrolled in the San Antonio Heart Study. 18 Our results may conflict with studies that found an association between sex hormones and blood pressure because the role of sex hormones in elevating blood pressure may differ among women who are already insulin-resistant and significantly overweight, or because the contribution of sex hormones to blood pressure, independent of weight loss and waist circumference reduction, is minimal.
The strengths of our report include its randomized study of weight loss interventions, which led to significant changes in body mass and blood pressure. Although we used mass spectrometric assays, which may be more sensitive to the low sex steroid levels typically observed in postmenopausal women, variance was still high at lower levels and may have biased estimates toward the null. 31 Finally, this study was a secondary analysis of a randomized trial not designed a priori to assess the interaction between estrogen use, sex hormones, and blood pressure; such a study, which randomized women to estrogen therapy and weight loss, is unlikely to be performed today because of logistics and cost. Of note, the DPP was conducted before the publication of the Women's Health Initiative trial results that led to decreases in estrogen prescription.
CONCLUSIONS
Lifestyle change targeting weight loss can reduce blood pressure in overweight glucose-intolerant women. The benefit of lifestyle change is observed in both estrogen users and nonusers, and the magnitude of blood pressure reduction does not differ by estrogen use. Therefore, successful attempts at weight loss and physical activity are expected to lead to lowered blood pressure, regardless of estrogen use. Additional investigation on the potential impact of hormone therapy on blood pressure among normal-weight glucose-tolerant populations, as well as on the potential mediating role of sex hormones in such populations, is needed.
